STARCOIN GROUP LIMITED
星 太 鏈 集 團 有 限 公 司

(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)

VOLUNTARY ANNOUNCEMENT
MEMORANDUM OF UNDERSTANDING IN RELATION TO STRATEGIC COOPERATION WITH HUAMEI HAIBO

This announcement is made by Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 25 March 2026, the Company has entered into a memorandum of understanding (the "**MOU**") in relation to a strategic cooperation with Huamei Haibo Biotechnology (Chongqing) Co., Ltd*. (華美海博生物科技(重慶)有限公司) ("**Huamei Haibo**").

THE MOU

Pursuant to the MOU, the parties intend to explore potential equity investment, asset restructuring, Web3.0 healthcare chain, business cooperation, joint market development, joint financing, and other capital operation arrangements, and the possibility of including Huamei Haibo or Huamei Haibo's relevant businesses and/or assets in a U.S. de-SPAC transaction involving the Group and/or its assets or businesses.

The parties also intend to explore potential arrangements regarding the integration, collaboration, injection, licensing, operation or commercialization of the following core assets and business modules:

1. the industrialized system for cell preparation and related turnkey equipment, including equipment production lines, turnkey equipment manufacturing capabilities, and equipment commercialization capabilities;

2. the upstream supplier system, procurement system, supplier management system, and supply chain management capabilities;

3. exclusive rights related to the target cells, including exclusive usage rights, exclusive commercialization arrangements, exclusive licenses, or other exclusive interests;

4. management rights, operational rights, maintenance rights, dispatching rights, and commercialization management systems relating to the relevant equipment;

5. supply systems, distribution channels, and sustainable supply capabilities for consumables required for cell preparation, cultivation, testing, delivery, and hospital-side application scenarios; and

6. hospital-side DataTech and FinTech management systems, including data management, data operations, data asset collaboration, settlement management, supply-chain finance, commercial collaboration, and other supporting digital management capabilities.

INFORMATION ON HUAMEI HAIBO

Huamei Haibo is a Chongqing-based biotechnology provider specializing in AI-driven cell manufacturing equipment and medical services. It is recognized for its innovation in modular cell factories and holds exclusive licenses for key cell standards and patent technologies from its strategic partners.

To the best of the Directors' knowledge, information, and belief, having made all reasonable enquiries, Huamei Haibo and its ultimate beneficial owners are third parties independent of the Company and its connected persons.

REASONS FOR AND BENEFITS OF THE MOU

The Board considers that entering into the MOU represents a strategic opportunity for the Group to strengthen its technological capabilities and broaden its development pipeline. Through the proposed cooperation, the Group will gain exclusive access to Huamei Haibo's proprietary cell standards, patented technologies and related technical services. Such exclusive access is expected to enhance the Group's research and development foundation, complementing its ongoing oral insulin programme and supporting the Group's longer-term ambition to expand its presence in the biotechnology and healthcare sectors. The proposed cooperation also provides a potential pathway for future commercialisation, industrialisation and market deployment of advanced cell-related technologies, thereby creating new revenue opportunities for the Group. In addition, Huamei Haibo's commitment to provide continuous technical support, documentation and assistance will help mitigate operational risks and ensure the smooth implementation of the authorised technologies.

The Board considers that entering into the MOU is in the interests of the Company and its shareholders as a whole.

GENERAL

This announcement is made by the Company on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed of the latest business development of the Group. The MOU sets out the framework of cooperation between the parties, and may or may not lead to the entering into of any definitive agreement.

The transactions contemplated under the MOU therefore may or may not proceed.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 25 March 2026

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.starcoingroup.com and www.irasia.com/listco/hk/starcoingroup.

* *For identification purpose only*